Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #18 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| GlaxoSmithKline Pharmaceuticals Limited (this stock) | 46,295 | 43.8 | 45.3% | 0.0% | 2.09% | 99 | 0 | 31 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 938 | 322 | 237 | ₹ |
| March 31, 2026 | 995 | 373 | 278 | ₹ |
| Dec. 31, 2025 | 1,041 | 400 | 296 | ₹ |
| Sept. 30, 2025 | 980 | 354 | 257 | ₹ |
| June 30, 2025 | 805 | 279 | 205 | ₹ |
| March 31, 2025 | 974 | 359 | 263 | ₹ |
| Dec. 31, 2024 | 949 | 308 | 230 | ₹ |
| Sept. 30, 2024 | 1,011 | 344 | 252 | ₹ |
| June 30, 2024 | 815 | 249 | 182 | ₹ |
| March 31, 2024 | 930 | 271 | 194 | ₹ |
| Dec. 31, 2023 | 805 | 65 | 46 | ₹ |
| Sept. 30, 2023 | 957 | 299 | 218 | ₹ |
| June 30, 2023 | 762 | 181 | 132 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 3,822 | 1,406 | 1,036 |
| March 31, 2025 | 3,749 | 1,260 | 928 |
| March 31, 2024 | 3,454 | 816 | 590 |
| March 31, 2023 | 3,252 | 836 | 611 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 903 | 397 | -737 | 55 | 848 |
| March 31, 2025 | 1,290 | -46 | -769 | 23 | 1,267 |
| March 31, 2024 | 582 | 9 | -561 | 31 | 551 |
| March 31, 2023 | 484 | 808 | -1,543 | 44 | 440 |
| March 31, 2022 | 811 | -406 | -524 | 35 | 776 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 4,324 | 2,285 | 2,098 | 0 | 0 | 3,785 | 1,779 | 1,102 | 274 | 458 |
| March 31, 2025 | 4,108 | 1,951 | 1,782 | 0 | 0 | 3,606 | 1,905 | 539 | 270 | 482 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
